English summaries translate the Chinese website. Links open the original source articles, which may be in Chinese.
R&D progress, marketing approval, cooperation and announcements - read Bio-Thera's latest public information by time.
GUANGZHOU, China – October 2026 – Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company...
Read more
Riyadh, Saudi Arabia / Guangzhou, China – August 18, 2026 – Avalon Pharma (Middle East Pharmaceutical Industries Company...
Guangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, t...
GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...
GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...
Guangzhou – Feb 26, 2025 – Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing...
• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera ...
Guangzhou, China/Riyadh, Saudi Arabia – February 3, 2026 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-st...
•Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia®developed by Bio-Th...
Guangzhou, China; November 10, 2025: Bio-TheraSolutions (688177:SH; “Bio-Thera”), a commercial-stage biopharmaceuticalco...
GUANGZHOU,China - Bio-Thera Solutions (688177.SH), a commercial-stage biopharmaceutical companydeveloping innovative the...
GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceuticalcompany developing a pipeline ...
Guangzhou, China / Jeddah, Saudi Arabia – September 15,2025 –Bio-Thera Solutions Inc.(688177:SH), a commercial-stage bio...